Brain-derived neurotrophic factor (BDNF) is the main candidate for neuroprotective therapeutic strategies for Huntington's disease. However, the administration system and the control over the dosage are still important problems to be solved. Here we generated transgenic mice overexpressing BDNF under the promoter of the glial fibrillary acidic protein (GFAP) (pGFAP-BDNF mice). These mice are viable and have a normal phenotype. However, intrastriatal administration of quinolinate increased the number of reactive astrocytes and enhanced the release of BDNF in pGFAP-BDNF mice compared with wild-type mice. Coincidentally, pGFAP-BDNF mice are more resistant to quinolinate than wild-type mice, suggesting a protective effect of astrocyte-derived BDNF. To verify this, we next cultured astrocytes from pGFAP-BDNF and wild-type mice for grafting. Wild-type and pGFAP-BDNF-derived astrocytes behave similarly in nonlesioned mice. However, pGFAP-BDNF-derived astrocytes showed higher levels of BDNF and larger neuroprotective effects than the wild-type ones when quinolinate was injected 30 days after grafting. Interestingly, mice grafted with pGFAP-BDNF astrocytes showed important and sustained behavioral improvements over time after quinolinate administration as compared with mice grafted with wild-type astrocytes. These findings show that astrocytes engineered to release BDNF can constitute a therapeutic approach for Huntington's disease.
Introduction
Huntington's disease (HD) is due to an abnormal expansion of a CAG codon in exon 1 of the huntingtin (htt) gene, resulting in a devastating cognitive and motor disorder, 1 which is characterized by a selective degeneration of projection neurons in the striatum. 2, 3 Many efforts have been made to develop treatments that counteract the symptomatology but an efficient therapy to alleviate or compensate the neural dysfunction or loss is not currently available.
Striatal neurons depend on brain-derived neurotrophic factor (BDNF) for function and survival, [4] [5] [6] [7] which is mainly provided by anterograde transport from corticostriatal afferents. 8, 9 Mutant huntingtin alters the BDNF function by an impairment in its transport, which results in deficient striatal BDNF levels. 10, 11 Furthermore, mutant huntingtin also deregulates the BDNF transcription in the cerebral cortex which, in turn, affects striatal BDNF levels. 12, 13 This reduction of BDNF levels affects the onset and severity of the disease in HD mouse models. 5 Moreover, upregulation of BDNF in different models of HD improves the disease symptomatology. [14] [15] [16] [17] BDNF can also be relevant in the regulation of cognitive alterations observed in HD. 18, 19 Thus, due to its prosurvival effects in striatal and cortical neuropathology, BDNF is the main candidate for neuroprotective therapies 20, 21 as it has been tested after intrastriatal administration of quinolinate (QUIN), an N-methyl-Daspartic acid receptor agonist used as an acute model of HD 22 , and in transgenic mouse models. 5 However, the main problem to use neurotrophic factors as therapeutic agents for neurodegenerative disorders is the chronic delivery system. 21, 23 Therefore, it is necessary to develop new systems for localized, conditional and safe delivery of neurotrophic factors.
The neuroprotective effects of BDNF have been shown by using different strategies such as transplantation of engineered cells, 24, 25 direct administration 5 or gene transfer. 26, 27 However, vector and virus toxicity, tumorigenesis and uncontrolled gene expression are often important problems to be solved. 21, 25, 28 Cell therapy has emerged as a putative tool to treat neurodegenerative diseases, genetically engineered cells being one of the most frequently considered strategies (for review see Dunnett and Rosser 29 ). In particular, engineered astrocytes could be good candidates to release neurotrophic factors. In fact, genetically modified astrocytes have been used with positive results in some models of neurodegeneration. 24, 30 This strategy could be relevant for HD as numbers of reactive astrocytes increase progressively concomitant to the disease progression. 3 Moreover, astrogliosis has been shown to be one of the specific hallmarks of disease progression in mouse models of HD. [31] [32] [33] Because of this increase in astrocytes in HD, and the fact that astrogliosis leads to increased glial fibrillary acidic protein (GFAP) promoter activation, one would predict that the use of this promoter in cell therapy would provide neurotrophic support at the time when it is critically needed.
In this work we show that transgenic astrocytes engineered to overexpress BDNF under control of the GFAP promoter release higher levels of BDNF than control astrocytes. This enhanced release of BDNF exerts neuroprotection of striatal neurons, which, in turn, results in long-term behavioral improvements.
Results

Generation and characterization of pGFAP-BDNF transgenic mice
We generated a new transgenic mouse line, pGFAP-BDNF mice, which overexpress BDNF regulated by the GFAP promoter. A visual scheme of the transgene construct is shown in Figure 1a . PCR analysis of different nervous and non-nervous system tissues showed transgene expression restricted to the central nervous system (Figure 1b) . Note the different levels of expression in several brain regions such as cortex, hippocampus and striatum ( Figure 1b ). Data obtained from the SHIRPA protocol indicated that the general appearance shown by pGFAP-BDNF mice was well groomed with a pink coloration in the ear and footpads (Figure 1c ). Neurosensorial items showed no gross neurological alterations in pGFAP-BDNF mice (Supplementary Figure 1A) . Moreover, there were no differences between wild-type (wt) and pGFAP-BDNF mice performing the Rotarod task (Supplementary Figure 1B) . Next, to analyze anxiety behavior and locomotor activity we used the open field. We observed that pGFAP-BDNF mice showed a similar locomotor behavior (Supplementary Figure 1C) , and identical mean speed, number of defecations and center/periphery ratios (data not shown). Also, pGFAP-BDNF mice showed body weight ( Figure 1d ) and whole-brain weight (Figure 1e ) similar to that of wt mice. Stereological volume measurements of brain regions such as motor cortex, hippocampus and striatum showed no differences between pGFAP-BDNF and wt mice (Figure 1f ). Western blot analyses showed similar GFAP levels in the hippocampus, motor cortex, prefrontal cortex, and striatum of pGFAP-BDNF and wt mice (Figure 1g ). BDNF enzyme-linked immunosorbent assay (ELISA) analysis indicated that the levels of this neurotrophin were not altered in pGFAP-BDNF mice (Figure 1h ).
Astrocytes from pGFAP-BDNF mice are viable and release BDNF specifically under proinflammatory conditions Tissue culture grown astrocytes from wt and pGFAP-BDNF mice (P1-P3 pups) capable of GFAP regulated overexpression of BDNF were shown to have equivalent astrocytic morphology (data not shown) and to be essentially pure by GFAP immunostaining (Figure 2a ). In addition, during in vitro amplification viability and survival of astrocytes from the two sources were also similar (Trypan blue procedure) (data not shown).
To study the response of these cultures to proinflammatory conditions, we induced astrogliosis in vitro. To this end, we used the proinflammatory cytokine tumor necrosis factor-a (TNF-a), which has been previously shown to increase selectively the BDNF production and release in pure astrocyte cultures. 34 Results showed that the basal content of BDNF in pGFAP-BDNF astrocytes was higher than in wt astrocytes (Figure 2b) . However, the amount of released neurotrophin was equal in both groups under control conditions but significantly higher levels of BDNF were secreted from pGFAP-BDNF than from wt astrocytes on TNF-a stimulation (Figure 2c ). We also tested the effect of the N-methyl-D-aspartic acid agonist QUIN on BDNF release in astrocyte cultures. However, QUIN itself did not modify the levels of BDNF (Supplementary Figure 2) . Taken together, these results show a normal morphology but increased BDNF protein expression in pGFAP-BDNF astrocytes, which was released in higher amounts only on inflammatory-like conditions. pGFAP-BDNF mice show striatal neuroprotection against acute administration of QUIN We next tested whether the release of BDNF after astrocyte stimulation in vitro would be translated into a neuroprotective effect after intrastriatal QUIN administration. To analyze astrogliosis in vivo, we first showed, by western blot analysis, that the expression level of GFAP in the striatum of wt and pGFAP-BDNF mice 1 and 7 days after QUIN administration was similar (Figures 3a and b) . In these experiments GFAP was rapidly upregulated and the elevated level was maintained for at least 1 week in ipsilateral striata of both genotypes, in comparison with sham controls, suggesting that transgene expression did not affect the capacity for a glial response. Next, we analyzed the levels of BDNF in wt and pGFAP-BDNF mice 1 and 7 days after QUIN administration. BDNF levels were upregulated from day 1 post-QUIN administration in lesioned striata of both wt and pGFAP-BDNF mice in comparison with their respective sham controls (Figure 3c ). This upregulation was still detectable after 1 week in both genotypes and, interestingly, BDNF levels were higher in the lesioned striata of pGFAP-BDNF mice than in that of wt mice (Figure 3c ). It is noteworthy that QUIN did not induce the BDNF upregulation due to direct astroglial NMDAR activation (Supplementary Figure 2) , suggesting it was essentially due to an astrocyte response to neuronal inflammation and injury. These results indicated a rapid and sustained induction in BDNF production by pGFAP-BDNF astrocytes after the excitotoxic insult. We then evaluated the extent of QUIN-induced lesion in both genotypes. At 7 days after Conditional release of BDNF in Huntington's disease A Giralt et al administration, the volume of the striatal lesion was smaller in pGFAP-BDNF mice than in wt mice, suggesting neuroprotective effects of transgenic astrocytes in pGFAP-BDNF mice (Figures 3d and e) . This protection was also observed by western blot analysis of dopamine and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) levels (Figure 3f ). Although wt mice intrastriatally injected with QUIN showed a decrease in the levels of DARPP-32 relative to wt sham-injected striata, the levels of DARPP-32 in the striata of QUIN injected pGFAP-BDNF mice were similar to those of their sham injected counterparts. In agreement with these findings, stereological cell counts showed a higher density of NeuN, DARPP-32 and parvalbumin-positive neurons in lesioned striata of pGFAP-BDNF mice than in lesioned striata of wt mice (Figures 4a-c) . However, no neuroprotective effect was observed in the number of choline acetyltransferase (ChAT)-positive cells, indicating that these cells were not protected against excitotoxicity by astrocytes expressing the pGFAP-BDNF transgene (Figure 4d ). These results indicated that in response to an intrastriatal excitotoxic insult, pGFAP-BDNF mice show regulated neuroprotection.
Wt and pGFAP-BDNF astrocytes grafted in Swiss nu-nu mice striata survive for long periods
We next tested whether grafting of pGFAP-BDNF mouse-derived astrocytes into Swiss nu-nu mice could be neuroprotective against intrastriatal QUIN lesion. We Note that non-nervous tissues such as heart and lungs show no RNA transgene expression due to GFAP specificity for neural populations. Appearance (c), body weight (d) and total brain weight (e) of wt and pGFAP-BDNF mice. Volume estimates for different brain regions (f). Analysis of GFAP (g) and BDNF (h) levels in different brain regions shows normal neurotrophin levels in both genotypes and no effect on GFAP protein expression in pGFAP-BDNF mice in comparison with wt mice. HIPO: hippocampus, CTX: motor cortex, STR: striatum, PFC: prefrontal cortex. Bars represent the mean±s.e.m. (n ¼ 5 per group at 6-8 weeks of age). Data were analyzed using the t-test when comparing two groups. To compare the body weight in both genotypes, we used the two-way ANOVA with Student's t-test as a post hoc.
Conditional release of BDNF in Huntington's disease A Giralt et al first characterized the survival and migration of grafted astrocytes from wt and pGFAP-BDNF mice in response to intrastriatal administration of phosphate-buffered saline (PBS) or QUIN. To track and characterize them after transplantation, we transduced cultured astrocytes with a retroviral vector for expression of enhanced green fluorescent protein (eGFP) 35 and grafted the resulting (an B50% proportion of eGFP-positive/GFAP-positive cells; data not shown) astrocytes into ipsilateral striata of Swiss nu-nu mice (Figures 5b3-b6 ). Histological analysis showed that eGFP-positive astrocytes were detectable at days 7 and 30 after grafting, indicating a sustained persistence of the graft (Figures 5b3-b6) . In shaminjected striata, astrocytes were mainly distributed in an elongated capsule-like structure surrounded by reactive astrocytes that formed a glial-like scar (Figures  5b3-b4) . Conversely, in QUIN-injected striata, grafted astrocytes were more disperse in comparison with shaminjected striata, although they were also surrounded by a glial-like scar (Figures 5b5-b6 ). To rule out the possibility of a downregulation of the transduced eGFP in grafted astrocytes, we performed additional experiments using astrocytes isolated from transgenic mice expressing eGFP under control of the b-actin promoter. 36 In these experiments, we obtained similar results showing low dispersion of grafted astrocytes surrounded by a glial-like scar (Supplementary Figure 3) .
Further morphological analysis of transplanted and endogenous astrocytes after QUIN administration showed a high density of reactive and stellate astrocytes with small and picnotic nuclei in the graft center and a considerably lower density of also reactive astrocytes outside the graft (Figure 6a pGFAP-BDNF astrocytes grafted in the striatum protect neurons against QUIN administration by BDNF upregulation Next, we examined whether pGFAP-BDNF grafted astrocytes provide neuroprotection to striatal cells against QUIN insult. At 7 or 30 days post-astrocyte transplantation (Figures 6b and e), QUIN or PBS were injected and the levels of BDNF in the grafted striata were examined (Figures 6d and g ).
We found that in the sham conditions, BDNF levels were equal when comparing mice grafted with wt or pGFAP-BDNF astrocytes at both time points (Figures 6d  and g ). However, the levels of BDNF increased when grafted striata were lesioned with QUIN, at 7 or 30 days after grafting (Figures 6d and g ). Interestingly, mice grafted with pGFAP-BDNF astrocytes showed a higher enhancement of this neurotrophin after QUIN administration than did mice grafted with wt astrocytes. These data correlated with a smaller lesion volume in mice grafted with pGFAP-BDNF astrocytes 7 and 30 days after grafting (Figures 6c and f) . Conditional release of BDNF in Huntington's disease A Giralt et al high BDNF levels which, in turn, protected striatal neurons even after long post-grafting periods.
Grafted pGFAP-BDNF astrocytes improve striatum-dependent behavioral tasks
To determine if the neuroprotection provided by pGFAP-BDNF grafted astrocytes against QUIN administration could produce behavioral improvements, we performed two tasks to check striatal function: the rotation test and the corridor task. Both tasks have been previously described in rodents to evaluate striatal function after unilateral QUIN administration. 35, 37 We performed a longitudinal study for both tasks in animals lesioned 30 days after grafting (Figures 8a and c) .
The rotation test was performed at 7, 15 and 30 days after lesion in unilaterally lesioned mice. As two-way repeated-measures analysis of variance (ANOVA) indicated (Po0.001), mice grafted with pGFAP-BDNF astrocytes showed less apomorphine-induced rotations as compared with mice implanted with wt astrocytes at all the time points analyzed (Figure 8b ). To further analyze the effects of pGFAP-BDNF-grafted astrocytes on striatum-dependent behavior, we also performed the corridor task. This task involves bilateral spatial awareness and a strong element of choice due to direct competition for the food pellets placed on either side of the corridor. 37 To avoid group bias we first collected data in a baseline pregrafting phase. As we expected, no differences were observed between mice (Figure 8d ). Thereafter, mice received a unilateral graft with wt or pGFAP-BDNF astrocytes and were examined to determine whether grafting per se could affect this task at two time points, 7 and 29 days after grafting. Neither wt nor .001 with respect to wt QUIN). When only two groups were compared, Student's t-test was used (corresponding to figure d, *Po0.05). Scale bar, 500 mm.
Conditional release of BDNF in Huntington's disease
A Giralt et al pGFAP-BDNF-grafted astrocytes affected this task when both groups were compared at 7 and 29 days after grafting. Next, sham or QUIN administration was performed 30 days after grafting and grafted mice were examined at 7 and 15 days after lesion. At 7 days after QUIN administration both wt and pGFAP-BDNF-grafted mice showed a slight but not significant increase in ipsilateral bias relative to their respective sham controls (Figure 8d ). At 15 days after lesion, striatal pathology was exacerbated by the administration of the dopaminergic agonist apomorphine. Wt and pGFAP-BDNFgrafted mice showed a significant increase in ipsilateral bias compared with their respective sham controls (Figure 8d ). In agreement with the results obtained in the rotation test, after the acute injection of apomorphine, mice grafted with pGFAP-BDNF astrocytes showed less ipsilateral bias relative to mice grafted with wt astrocytes after QUIN lesion. Taken together, these findings show that pGFAP-BDNF-grafted astrocytes were significantly more neuroprotective and induced larger behavioral improvements than wt grafted astrocytes even 60 days after transplantation.
Discussion
Here we show a novel neuroprotective therapy for HD using BDNF-engineered astrocytes. To this end, we generated and characterized a new transgenic mouse line that overexpresses BDNF under control of the GFAP promoter (pGFAP-BDNF mice). In vitro we show that only under inflammation-like conditions, pGFAP-BDNF mice-derived astrocytes expressed and released more BDNF than wt mouse-derived astrocytes. Accordingly, pGFAP-BDNF transgenic mice showed an upregulation of BDNF levels and neuroprotection of striatal neurons after intrastriatal QUIN administration in comparison with wt mice. To evaluate the long-term benefits of the pGFAP-BDNF-derived astrocytes, we performed striatal grafts of cultured astrocytes from wt and pGFAP-BDNF mice and compared their effect after intrastriatal administration of PBS or QUIN. pGFAP-BDNF-grafted astrocytes produced long-term neuroprotective effects when compared with wt grafted astrocytes which, in turn, also improved striatum-dependent behavioral tasks after intrastriatal QUIN administration. Presently, there is no efficient treatment for HD patients. 38, 39 A large number of clinical trials, testing pharmacological approaches, have so far produced discouraging results. 39, 40 Neuroprotective strategies using several growth factors have also been proposed for HD. [41] [42] [43] Among them, BDNF, so far the best candidate, has been shown to modulate the onset and severity of motor and cognitive functions in HD mouse models 5, 18, 19, 44 and to participate in the disruption of the cortico-striatal glutamatergic transmission that occurs in HD. 45, 46 Furthermore, transgenic mice overexpressing BDNF in the cerebral cortex, when cross-mated with R6/1 Conditional release of BDNF in Huntington's disease A Giralt et al mice, improve several morphological and behavioral symptoms. 15 As per these data, the development of a putative neuroprotective therapy based on BDNF could be a successful treatment strategy for the disease. 20, 21 Several methods have been tested to deliver neurotrophic factors in the central nervous system. Exogenous supply has been examined using viral infection and lipotransfection to promote the expression of protective molecules. However, this proved to be too invasive for the endogenous cells and not sufficiently diffusible in the striatum. 21, 25, 28 Grafting of engineered cells for the release of protective molecules has also been proposed as one of the most promising therapeutic tools for HD. 29 We have previously shown that BDNF-overexpressing cell lines prevent the death of striatal projecting neurons in a rat model of HD. 43 However, the methodology used in these studies cannot be used for chronic pathologies because of the likelihood of tumor generation by brainimplanted fibroblasts. 47 The use of stem cells in HD cell therapy has also emerged as a powerful tool for the release of striatal neuron protecting neurotrophic factors. 35, 48, 49 Owing to their teratogenic potential, embryonic stem cells are, so far, not useful for clinical use. Neural cells may be a better candidate source for the overexpression of BDNF. However, as an excessive amount of this neurotrophin is deleterious, 42 its release must be controlled. 48, 49 To resolve this important issue, here we used engineered astrocytes that release high levels of BDNF only in pathological situations. Our study findings showed successful cell integration without aberrant proliferation. pGFAP-BDNF-grafted astrocytes were restricted to a scar-like structure mainly formed by endogenous reactive astrocytes, and showed low levels of migration as expected. 50, 51 These findings indicate that transplanted astrocytes engineered for BDNF-secreting may be safe for gene therapy of not only HD but also for other neurological disorders where neuronal death is BDNF dependent and astrogliosis is associated. 
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Our results also showed increased levels of migration when grafted astrocytes were subjected to QUIN administration, suggesting that they respond to endogenous stimuli. This is in agreement with previous works that showed a different behavior of grafted cells after excitotoxicity. 52 In addition, we show an increase in GFAP expression after QUIN administration. Thus, QUIN-induced excitotoxicity not only increases astrocyte mobility at the cellular level but also increases the expression of GFAP, indicating activation of these glial cells. We were able to take advantage of this reaction because in our construct BDNF production is controlled by the GFAP promoter. Importantly, HD patients show high levels of astrogliosis 3 and this pathological hallmark also shows a progressive increase in all tested animal models of HD in correlation with the degenerative process. [31] [32] [33] 53 Interestingly, our study results show that pGFAP-BDNF transgenic astrocytes release high levels of this neurotrophin only on stimulation. We did not find differences in BDNF release between pGFAP-BDNF astrocytes and wt astrocytes in basal conditions. Moreover, although we show a similar pattern of BDNF production and release by wt astrocytes after inflammation-like conditions, to that previously described, 34, 54 however, this inflammationlike stimulation resulted in a higher release of BDNF from pGFAP-BDNF astrocytes than from wt astrocytes. Similar to the in vitro situation studies, in our in vivo experiments, BDNF was only overexpressed when the striatum was subject to an excitotoxic insult. Altogether, these results indicate that GFAP-controlled BDNF release may constitute a self-regulated neuroprotective strategy for HD allowing BDNF release in a severity-dependent manner during disease progression. Such conditional regulation is highly desirable to prevent the undesired effects of uncontrolled BDNF release. In line with this hypothesis, similar strategies to release NGF have been proposed for other neurodegenerative diseases. 24 Our long-term experiments showed that astrocytes grafted 30 days before QUIN injury can be induced to overexpress BDNF, which results in neuronal protection and behavioral improvements. The viability and functionality overtime of a graft is a critical issue that merits research efforts. 25 We have achieved this objective from a morphological, biochemical and behavioral point of view. pGFAP-BDNF grafted astrocytes remained functional for neuroprotection against QUIN administration even 1 month after grafting. Furthermore, this protection was sustained for, at least, four additional weeks after QUIN administration as we showed by different striatum-dependent behavioral tasks. Therefore, these genetically modified astrocytes could be a good tool for neuroprotection studies in genetic animal models of HD.
Although BDNF has a clear survival effect on striatal neurons, 6, 43 we cannot rule out that the upregulated BDNF levels produced by pGFAP-BDNF-grafted astrocytes induced synergistic effects with other released molecules during inflammation and thereby exert more neuroprotection. 34 However, it is noteworthy that BDNF also increases neurogenesis in QUIN-lesioned striatum, 55 and the induction of neostriatal neurogenesis produces a functional improvement in R6/2 mice. 56 Thus, all these results together may suggest that the combined neuroprotective and cell replacement effects induced by BDNF could help to slow disease progression.
In conclusion, our data provide a putative therapeutic approach for HD through grafting stable and functional astrocytes with conditional upregulated BDNF Conditional release of BDNF in Huntington's disease A Giralt et al expression. This therapeutic strategy not only protects striatal neurons against QUIN injury, but also produces behavioral improvements. We suggest that this approach should be considered for future treatment of HD patients.
Materials and methods
Generation of pGFAP-BDNF/c-myc transgenic mice
The rat GFAP 5 0 flanking sequence spans bp À2570 to +27 relative to the transcriptional start site. This promoter is Conditional release of BDNF in Huntington's disease A Giralt et al fused to the last 18 bp of exon 2 of the rabbit b-globin gene followed by intron 2 and the first 51 bp of exon 3. The BDNF c-myc cDNA was cloned into the third exon of the rabbit b-globin gene, with approximately 50 bp of this exon at its 3 0 end. The cDNA is followed by the SV40 polyadenylation sequence. The vector backbone (pSK+) was removed by XhoI digestion and a 5 kb fragment was injected into the male pronucleus to generate transgenic mice. A DNA segment encoding 10 amino acids of the c-myc protein was fused to the complete mouse BDNF protein sequence 57 to serve as a tag facilitating detection of the BDNF transgene. Both, RNA and protein transgene products are readily distinguishable from endogenous BDNF RNA and protein. This construct has been previously used 58 in the preparation of an adenovirus vector. The BDNF produced from this vector was clearly bioactive, supporting neuronal survival in vitro as well as in vivo. Thus the c-myc tag did not interfere with BDNF activity. The GFAP promoter was obtained from J Henderson. BDNF c-myc cDNA was kindly provided by Y Barde.
Animal care
We used 6-to 8-week-old male inbred C57/BL6 wt and pGFAP-BDNF mice, expressing the BDNF transgene under control of the GFAP promoter. For transplantation experiments we used adult nude mice, Swiss nu-nu; 10-to 12-week old (Charles River Laboratories, Les Oncis, France). Animals were housed in mixed genotype groups. All experiments were blind-coded regarding genotype, and data were recorded for analysis by microchip mouse number. Animals were maintained on ad libitum food and water diet in a colony room kept at a constant temperature (20-22 1C) and 40-60% relative humidity on a 12 h light/dark cycle. All procedures were according to European Community guidelines for the care and use of laboratory animals (86/609//EEC), and were approved by the animal care committee of the University of Barcelona, and by the regional autonomous government (Generalitat de Catalunya). For genotyping, DNA was obtained from tail biopsy and processed for PCR. The primers used for DNA amplifications were: 5 0 globin (intron included in construct): 5 0 -GCTTGGAT CCTGAGAACTTCAGG-3 0 and BDNF 3 0 2 (in BDNF): 5 0 -CT GTCACACACGCTCAGCTC-3 0 . PCR reactions were according to Invitrogen (El Prat del Llobregat, Barcelona, Spain) TaqMan gene expression assays instructions. PCR fragments were resolved in agarose gels.
Characterization of the pGFAP-BDNF transgene expression
Total RNA from lung, heart and several brain regions (cortex, hippocampus and striatum) from 6-to 8-weekold mice (n ¼ 4) was extracted using the Total RNA Isolation Nucleospin RNA II Kit (Macherey-Nagel, Dü ren, Germany). Total RNA (500 ng) was used to synthesize cDNA with random primers from the StrataScript First Strand cDNA Synthesis System (Stratagene, La Jolla, CA, USA). The cDNA synthesis was performed at 42 1C for 60 min in a final volume of 20 ml according to manufacturer's instructions. The cDNA was then analyzed by PCR, using the abovedescribed primers, and PCR fragments were resolved in agarose gels.
Astrocyte cultures
Primary astrocyte cultures were obtained from P1 to P3 wt and pGFAP-BDNF mouse pups by cortical dissections, and removal of the meninges. Extracted tissue was dissociated and placed in 25 cm 2 flasks in a MEM 1 Â conditioned media NM-15 (20% fetal bovine serum; Gibco-BRL, Renfrewshire, Scotland, UK; D-Glucose 90 mM; Buchs, Switzerland) with L-glutamine and Earle's salts (Gibco-BRL) and placed in an incubator at 37 1C with 5% CO 2 . A tail biopsy was obtained from each pup for genotyping. After two passages cultures were purified by agitating in a shaker during 10 min at 400 r.p.m. Medium with undesired floating cells was replaced and flasks were placed in an incubator for 2 h at 37 1C. Next, flasks were agitated again for 16-18 h at 250 r.p.m. Finally, medium with floating cells was replaced with new medium.
BDNF release from astrocytes
At 24 h after purification, astrocyte cultures were trypsinized, seeded at 1 Â 10 6 cells per P100 and allowed to reach 100% confluence. Next, cells were deprived of serum during a 3-day period following, and the medium was collected and stored at À80 1C. Astrocytes were then stimulated during 72 h in serum-free media containing 10 ng ml À1 of TNF-a (Sigma, St Louis, MO, USA) or only vehicle. Medium was collected and stored at À80 1C, until tested for induction of BDNF synthesis and release. Cell homogenates to evaluate intracellular BDNF levels were produced in PBS, 1% Nonidet P40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM PMSF, 10 mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 2 mg ml À1 sodium orthovanadate lysis buffer. To reduce biological variance, we performed three to five independent experiments and each sample was measured in triplicates in ELISA assay.
Astrocytes transduction
Astrocyte cultures were transduced using retroviral vectors carrying the construct peGFP-CMVluc. 35 Briefly, cells in the proliferation stage, before astrocyte purification, were infected during 8 h in 3 consecutive days using viral supernatants from 293GPG packaging cells diluted 1:3 in fresh normal medium. Polybrene 8 mg ml À1 was added to enhance viral internalization. After the third day of infection, cells were passed normally and were used for cell transplantation, as described for nontransduced cells.
Striatal transplantations
After purification, astrocytes were grown to 100% confluence and then used for transplantation in adult (10-to 12-week-old) Swiss nu-nu mice (n: 5-7 per genotype). Wt and pGFAP-BDNF astrocytes were detached by trypsinization, collected by addition of 10 ml cold NM-15 medium to each flask, centrifuged at 1000 g for 5 min and the pellet was then resuspended in 1 ml of serum-free NM-15 medium. Finally, the cell suspension was centrifuged at 1000 g for 5 min and the pellet was diluted to a concentration of 4 Â 10 5 cells per ml, the astrocyte concentration used for transplantation. In the last three steps, NM-15 medium was supplemented with 33 mM DNAase I (Sigma). To test viability of astrocytes, we stained cells with Trypan blue (Sigma) and counted alive cells before (B100% of cell viability) and after ), we grafted cells at four sites of the striatum of Swiss nu-nu mice at the following coordinates (millimeters); anteroposterior (AP), +0.8 and +0.33; lateral (L), +2.0 and +2.55 from bregma, and dorsoventral (DV), À2.25 and À2.75 from dura. Cells were injected over 2 min leaving the cannula in place for additional 5 min, and then slowly removing the cannula. The animals were monitored for 2 h after administration and then returned to the housing facility for 7 or 30 days. After these periods, animals from experimental groups were subjected to intrastriatal administration of QUIN or vehicle.
Striatal lesions
Anesthetized wt, pGFAP-BDNF and grafted SWISS nu-nu mice (n: 5-7 per genotype) were stereotaxically injected into the striatum with either a 0.5 ml of QUIN (15 nmol; Sigma) or vehicle at following coordinates (in millimeters): AP, +0.6, L, +2.0 from bregma and DV, À2.7 from dura. QUIN was injected more than 1 min after which the cannula was left in the place for a further 5 min period, and then slowly removed. The animals were monitored for 2 h after injection and then returned to the housing facility for 1, 3 or 7 days (wt and pGFAP-BDNF animals) and for 1, 7, 15 or 30 days for grafted Swiss nu-nu mice.
Enzyme-linked immunosorbent assay
Brain-derived neurotrophic factor content in different brain regions, cell homogenates and their corresponding culture media was determined using E max Immunoassay System Kit (Promega, Madison, WI, USA), according to the manufacturer's instructions. Brains regions of deeply anesthetized mice (n: 5-7) were dissected, placed in ice and rapidly frozen in dry ice. Samples were then sonicated in lysis buffer (PBS, 1% Nonidet P40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM PMSF, 10 mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 2 mg ml À1 sodium orthovanadate) and centrifuged (25 min Â 13 200 r.p.m.). Supernatants were collected and the protein contents were measured by Detergent Compatible Protein Assay (Bio-Rad, Hercules, CA, USA). Total protein was analyzed by using 150 mg samples, for each point, diluted 1:3 in blocking or sample buffer. Duplicate serial dilutions of recombinant BDNF (0-500 pg ml
À1
) were used to generate a standard curve. Each sample was analyzed three times.
Western blot analysis
Mice (5-to 6-week old; n: 5-7 per genotype) were deeply anesthetized in a CO 2 chamber, the brains quickly removed, brain regions dissected, frozen in dry ice and stored at À80 1C until use. Briefly, tissue was sonicated in 250 ml of lysis buffer (PBS, 1% Nonidet P40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM PMSF, 10 mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 2 mg ml À1 sodium orthovanadate) and centrifuged at 12 000 r.p.m. for 20 min. Proteins (15 mg) from different brain regions were analyzed by 7.5% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes (Millipore, Bredford, MA, USA). Gel blots were blocked in TBS-T (150 mM NaCl, 20 mM Tris-HCl (pH 7.5), 0.05% Tween 20) with 5% non-fat dry milk and 5% bovine serum albumin. Immunoblots were probed with anti-DARPP-32 1:10 000 (Chemicon, Temecula, USA) or Anti-GFAP 1:1000 (Dako A/S, Glostrup, Germany). All blots were incubated, with the primary antibody, overnight at 4 1C in PBS 0.02% sodium azide buffer with shaking. After several washes in TBS-T, blots were incubated with IgG HRP-conjugated anti-mouse or anti-rabbit antibodies (Promega) and developed using the ECL western blotting analysis system (Santa Cruz Biotechnology, Santa Cruz, CA, USA). A monoclonal anti-b-tubulin antibody (Sigma) was used as a loading control.
Immunohistochemistry
Animals were deeply anesthetized with pentobarbital (60 mg kg
À1
) and intracardially perfused with a 4% paraformaldehyde solution in 0.1 M sodium phosphate, pH 7.2. Brains were removed and post-fixed for 2 h in the same solution, cryoprotected with 30% sucrose in PBS with 0.02% sodium azide and frozen in dry-ice cooled isopentane. Serial coronal sections (30 mm) obtained with a cryostate were processed for immunohistochemistry as free floating.
The sections were washed three times in PBS, permeabilized 15 min by shaking at room temperature with PBS containing 0.3% Triton X-100 and 3% normal goat serum (Pierce Biotechnology, Rockford, IL, USA). After three washes, brain slices were incubated overnight by shaking at 4 1C with the corresponding primary antibodies in PBS with 0.02% sodium azide 1:200 buffer: anti-GFAP (Dako A/S), anti-GFP 1:2500 (Upstate Biotechnology, NY, USA) and/or anti-BDNF 1:1000 (Alomone, Jerusalem, Israel). After primary antibody incubation, slices were washed three times and then incubated 2 h shaking at room temperature with subtype-specific fluorescent secondary antibodies: Cy3 goat anti-rabbit (1:100) and Cy2 goat anti-mouse (1:100) (both from Jackson ImmunoResearch, West Grove, PA, USA). No signal was detected in controls incubated in the absence of the primary antibody.
For diaminobenzidine immunohistochemistry experiments, endogenous peroxidases were blocked for 30-45 min in PBS containing 10% methanol and 3% H 2 O 2 . Then, nonspecific protein interactions were blocked with normal serum or bovine serum albumin. Tissue was incubated overnight at 4 1C with the following primary antibodies: anti-NeuN (1:1000; Chemicon) anti-DARPP32 (1:10 000; Chemicon), antiparvalbumin (1:1250; Sigma), anti-ChAT (1:500; Upstate) or anti-GFAP (1:1000; Sigma). Sections were washed three times in PBS and incubated with a biotinylated secondary antibody (1:200; Pierce) at room temperature for 2 h. The immunohistochemical reaction was developed using the ABC kit (Pierce) and visualized with diaminobenzidine. No signal was detected in controls in which the primary antibodies have been omitted. Cresyl violet staining was performed as described previously. 9 
Stereology
Volume estimates for striatum, hippocampus and cortex were performed as previously described. 5, 46, 59 Unbiased blind counting relative to genotype and condition was performed using the Computer Assisted Stereology Toolbox (CAST) software (Olympus Danmark A/S, Ballerup, Denmark). To determine the neuronal subpopulations densities (neurons per mm 3 
) in the lesion
Conditional release of BDNF in Huntington's disease A Giralt et al area and the contralateral striatum (1.05-0.15 mm from bregma), we used the dissector counting procedure in coronal sections spaced 240 or 120 mm apart.
Adjacent version of the corridor task
Behavioral effects were analyzed using a previously described apparatus sensitive to striatal lesions adapted for mice 37 consisting of a rectangular 50 cm long Â 5 cm wide Â 15 cm deep black metacrylate box. Plastic dishes, 1 cm diameter Â 0.5 cm deep, containing one sugar pellet (20 mg; Bioserve, Frenchtown, NJ, USA), were placed along the corridor floor touching either one or the other side walls. Ten plastic dishes were arranged in five pairs at 5 cm intervals. Mice were food-deprived to B85% of their normal body weight. They were habituated to the corridor, and learned to search for, and retrieve pellets, over a 15 min period on the day before baseline testing. On testing days, trials began by releasing the mouse at one end of the baited corridor and allowing it to explore. A 'retrieval' involved a nose poke into a lid, regardless of whether a pellets was taken from it, that defined the side according to the mouse's body axis. Trials were completed after 10 retrievals, or a 5 min period.
Mice performance was tested in five conditions: at baseline, post-graft 1, post-graft 2, and post-lesion 1 and post-lesion+apomorphine (baseline was performed 2 days before graft, post-graft 1 and 2 were performed on days 7 and 29 post-astrocytes grafting and post-lesion 1, and finally, post-lesion+apomorphine were performed at 7 and 15 days post-QUIN administration). On postlesion+apomorphine day, 5 min before testing, the animals were administered 2 mg kg À1 apomorphine hydrobromide (Sigma) buffered in 0.9% saline.
Rotation test
To further study the behavioral effects of intrastriatal grafted astrocytes, we used a previously described open field apparatus. 35 Behavioral data were recorded using a video capture system (Videotrack 512; Electronique lyonnais, Lyon, France). After administration of 2 mg kg À1 apomorphine hydrobromide (Sigma) buffered in 0.9% saline, animals were placed into the register area for a 15 min period and their rotational behavior was recorded at 5 min intervals. We then compared the curves for each genotype.
Statistical analysis
All results were expressed as the mean±s.e.m. for each genotype or group. For the statistical analysis of stereological, behavioral and biochemical experiments, the unpaired Student's t-test, one-way ANOVA, two-way ANOVA, two-way repeated-measures ANOVA and Fisher's exact test were used when appropriate and specified at the corresponding figure legend. Po0.05 was considered significant.
